Funding will accelerate development of manufactured pancreatic beta cells capable of restoring insulin production using Syntax’s Cellgorithm™ technology Syntax Bio, a synthetic biology company ...

In recent years, we have come to appreciate that loss or dysfunction of insulin-producing islet beta cells underlies virtually all major forms of diabetes mellitus. In type 1 diabetes, beta cells ...

I am deeply humbled by the decades of support from people around the world. It is an honor to share this painful yet ...

Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or transfusion-dependent beta ...

For the 40 million Americans living with diabetes, researchers are pursuing treatments that go beyond lifelong insulin injections. One emerging approach — reprogramming a patient’s own cells into ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) restored insulin production and ended severe hypoglycemia in adults with type 1 ...

In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a bold new front. With $1 million in funding from Breakthrough T1D, the ...

People with type 1 diabetes must constantly rely on insulin injections or pumps, usually for the rest of their life after diagnosis. The autoimmune disease destroys the cells that produce the hormone, ...

Rapid advances in cell therapy have resulted in complex processes. As they move toward the clinic, manufacturers are attempting to scale up or scale out the processes using legacy equipment that often ...